FDA accepts supplemental new drug application for zanubrutinib (Brukinsa) for treatment of adults with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy

Submission for this small molecule inhibitor of Bruton’s tyrosine kinase include results from single-arm phase 2 MAGNOLIA trial in patients with relapsed or refractory disease, with supportive data from a global phase 1/2 trial in patients with B-cell malignancies.

Source:

Biospace Inc.